轻、中度高血压病病人口服多沙唑嗪控释片与贝那普利比较

目的 :评价多沙唑嗪控释片对轻、中度高血压病病人降压有效性及安全性。方法 :采用双盲、双模拟、随机化、平行对照研究方法。 5 8例服多沙唑嗪控释片 4mg ,poqd× 8wk ,5 6例服贝那普利 10mg ,poqd× 8wk。此外 ,对 3 3例开放服多沙唑嗪控释片 4mg ,qd× 8wk。服药前后行 2 4h动态血压监测 (2 4hABPM)。结果 :2组均能有效地降压 ,有效率分别为 81%及 77% (P >0 .0 5 )。多沙唑嗪组不良反应明显少于贝那普利组 (3 %及 2 0 % ) ,P <0 .0 1,无体位性低血压及反射性心动过速。 2 4hABPM示等幅度降日间血压及夜间血压。谷 /峰比值 :SBP为 0 .69,DBP为 0 .5 9。结论 :多沙唑嗪控释片是一种有效安全的长效肾上腺素α1受体阻滞剂。

Comparison between doxazosin controlled release tablet and benazepril in patients with mild to moderate essential hypertension

AIM:To evaluate the efficacy and safety of doxazosin controlled release tablets in patients with mild to moderate essential hypertension. METHODS: A multicenter,double blind,double similarly randomized parallel study was designed. Fifty eight patients received doxazosin (4 mg, po, qd) and fifty six patients received benazepril (10 mg, po, qd) for 8wk. Another 33 patients in open trial received doxazosin with 24 h ambulatory blood pressure monitoring (ABPM) before and after treatment 4 mg, po , qd for 8 wk. RESULTS: The blood pressure significantly decreased after treatment with doxazosin and benazepril and the effective rates were 81% and 77 %, respectively at the end of 8 wk. And the adverse reactions were 3 % and 20 % with no orthostatic hypotension.24h ABPM showed significantly daytime and nighttime blood pressure smoothly reduction and T/P ratio:SBP:0.69, DBP:0.59. CONCLUSION: Doxazosin controlled release tablets is an effective, safe and long acting α 1 receptor blocker and has less adverse reaction than benazepril in treating mild to moderated essential hypertension.